AKT1 and hepatocellular carcinoma: USP22 can promote multidrug resistance (MDR) in hepatocellular carcinoma cells by activating the SIRT1/AKT/MRP1 pathway, which contributes to tumorigenesis and progression of hepatocellular carcinoma.